ANI Pharmaceuticals Inc (ANIP): Cash & Equivalents
$285.58M
As of 2025-12-31
$360.21M
As of 2026-06-30
+80.9%
3-year compound annual growth
+105.1%
5-year compound annual growth
+6.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $285.58M | +97.1% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $144.86M | -34.5% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $221.12M | +358.5% | 2026-02-27, Balance as of period end |
| 2022-12-31 | $48.23M | -51.9% | 2025-02-28, Balance as of period end |
| 2021-12-31 | $100.30M | n/m | 2024-02-29, Balance as of period end |
| 2020-12-31 | $7.86M | -87.4% | 2023-03-09, Balance as of period end |
| 2019-12-31 | $62.33M | +44.9% | 2022-03-15, Balance as of period end |
| 2018-12-31 | $43.01M | +38.1% | 2021-03-11, Balance as of period end |
| 2017-12-31 | $31.14M | +13.8% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $27.36M | -82.3% | 2019-02-27, Balance as of period end |
| 2015-12-31 | $154.68M | -8.5% | 2018-02-27, Balance as of period end |
| 2014-12-31 | $169.04M | n/m | 2017-03-02, Balance as of period end |
| 2013-12-31 | $11.11M | n/m | 2016-02-23, Balance as of period end |
| 2012-12-31 | $11.0K | -100.0% | 2014-02-28, Balance as of period end |
| 2011-12-31 | $57.23M | +50.0% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $38.16M | +27.8% | 2013-02-28, Balance as of period end |
| 2009-12-31 | $29.86M | n/a | 2012-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $285.58M | +97.1% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $752.50M | +66.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $372.26M | +53.8% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $198.69M | +98.7% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $231.25M | +227.7% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $205.40M | +106.4% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $177.69M | -44.4% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
Compare ANIP, HRMY, IONS, MDGL side by side · Screen every company in Pharmaceutical Preparations ↗